Faslpr gene dosage tunes the extent of lymphoproliferation and T cell differentiation in lupus

Faslpr gene dosage tunes the extent of lymphoproliferation and T cell differentiation in lupus

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 258(2024) vom: 19. Jan., Seite 109874
1. Verfasser: Bohat, Ritu (VerfasserIn)
Weitere Verfasser: Liang, Xiaofang, Chen, Yanping, Xu, Chunyu, Zheng, Ningbo, Guerrero, Ashley, Hou, Jiakai, Jaffery, Roshni, Egan, Nicholas A, Li, Yaxi, Tang, Yitao, Unsal, Esra, Robles, Adolfo, Chen, Si, Major, Angela M, Elldakli, Hadil, Chung, Sang-Hyuk, Liang, Han, Hicks, M John, Du, Yong, Lin, Jamie S, Chen, Xiqun, Mohan, Chandra, Peng, Weiyi
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2024
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Autoimmune disease FAS Genetics Lupus
LEADER 01000caa a22002652 4500
001 NLM366046292
003 DE-627
005 20240410232339.0
007 cr uuu---uuuuu
008 231227s2024 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2023.109874  |2 doi 
028 5 2 |a pubmed24n1371.xml 
035 |a (DE-627)NLM366046292 
035 |a (NLM)38113962 
035 |a (PII)S1521-6616(23)00638-1 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Bohat, Ritu  |e verfasserin  |4 aut 
245 1 0 |a Faslpr gene dosage tunes the extent of lymphoproliferation and T cell differentiation in lupus 
264 1 |c 2024 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 02.01.2024 
500 |a Date Revised 10.04.2024 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. 
520 |a Sle1 and Faslpr are two lupus susceptibility loci that lead to manifestations of systemic lupus erythematosus. To evaluate the dosage effects of Faslpr in determining cellular and serological phenotypes associated with lupus, we developed a new C57BL/6 (B6) congenic lupus strain, B6.Sle1/Sle1.Faslpr/+ (Sle1homo.lprhet) and compared it with B6.Faslpr/lpr (lprhomo), B6.Sle1/Sle1 (Sle1homo), and B6.Sle1/Sle1.Faslpr/lpr (Sle1homo.lprhomo) strains. Whereas Sle1homo.lprhomo mice exhibited profound lymphoproliferation and early mortality, Sle1homo.lprhet mice had a lifespan comparable to B6 mice, with no evidence of splenomegaly or lymphadenopathy. Compared to B6 monogenic lupus strains, Sle1homo.lprhet mice exhibited significantly elevated serum ANA antibodies and increased proteinuria. Additionally, Sle1homo.lprhet T cells had an increased propensity to differentiate into Th1 cells. Gene dose effects of Faslpr were noted in upregulating serum IL-1⍺, IL-2, and IL-27. Taken together, Sle1homo.lprhet strain is a new C57BL/6-based model of lupus, ideal for genetic studies, autoantibody repertoire investigation, and for exploring Th1 effector cell skewing without early-age lymphoproliferative autoimmunity 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Autoimmune disease 
650 4 |a FAS 
650 4 |a Genetics 
650 4 |a Lupus 
700 1 |a Liang, Xiaofang  |e verfasserin  |4 aut 
700 1 |a Chen, Yanping  |e verfasserin  |4 aut 
700 1 |a Xu, Chunyu  |e verfasserin  |4 aut 
700 1 |a Zheng, Ningbo  |e verfasserin  |4 aut 
700 1 |a Guerrero, Ashley  |e verfasserin  |4 aut 
700 1 |a Hou, Jiakai  |e verfasserin  |4 aut 
700 1 |a Jaffery, Roshni  |e verfasserin  |4 aut 
700 1 |a Egan, Nicholas A  |e verfasserin  |4 aut 
700 1 |a Li, Yaxi  |e verfasserin  |4 aut 
700 1 |a Tang, Yitao  |e verfasserin  |4 aut 
700 1 |a Unsal, Esra  |e verfasserin  |4 aut 
700 1 |a Robles, Adolfo  |e verfasserin  |4 aut 
700 1 |a Chen, Si  |e verfasserin  |4 aut 
700 1 |a Major, Angela M  |e verfasserin  |4 aut 
700 1 |a Elldakli, Hadil  |e verfasserin  |4 aut 
700 1 |a Chung, Sang-Hyuk  |e verfasserin  |4 aut 
700 1 |a Liang, Han  |e verfasserin  |4 aut 
700 1 |a Hicks, M John  |e verfasserin  |4 aut 
700 1 |a Du, Yong  |e verfasserin  |4 aut 
700 1 |a Lin, Jamie S  |e verfasserin  |4 aut 
700 1 |a Chen, Xiqun  |e verfasserin  |4 aut 
700 1 |a Mohan, Chandra  |e verfasserin  |4 aut 
700 1 |a Peng, Weiyi  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 258(2024) vom: 19. Jan., Seite 109874  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:258  |g year:2024  |g day:19  |g month:01  |g pages:109874 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2023.109874  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 258  |j 2024  |b 19  |c 01  |h 109874